Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 9/20 | 0.45 |
| ▸ | KYAT1 | Q16773 | 2/20 | 0.45 |
| ▸ | KYAT3 | Q6YP21 | 2/20 | 0.45 |
| ▸ | GOT1 | P17174 | 1/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 4/20 | 0.36 |
| ▸ | DUT | P33316 | 2/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4067713 | 1.00 | AADAT (0.45) | AADATKYAT1KYAT3GOT1CACNA1S | |
| SCHEMBL4072394 | 0.93 | AADAT (0.43) | AADATKYAT1KYAT3GOT1CACNA1S | |
| SCHEMBL4067680 | 0.84 | PYGL (0.36) | AADATKYAT1KYAT3GOT1CACNA1S | |
| SCHEMBL4071623 | 0.84 | AADAT (0.37) | AADATKYAT1KYAT3GOT1DUT | |
| SCHEMBL4067889 | 0.84 | AADAT (0.49) | AADATKYAT1KYAT3GOT1DUT | |
| SCHEMBL13878903 | 0.84 | AADAT (0.49) | AADATKYAT1KYAT3GOT1DUT | |
| SCHEMBL13878891 | 0.84 | AADAT (0.37) | AADATKYAT1KYAT3GOT1DUT | |
| SCHEMBL4063334 | 0.83 | DUT (0.34) | AADATDUT | |
| SCHEMBL5628897 | 0.81 | AADAT (0.52) | AADATKYAT1KYAT3GOT1CACNA1S | |
| SCHEMBL4072393 | 0.78 | DUT (0.39) | CACNA1SDUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099176-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099176-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-1819332-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LTD (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-1819332-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | Prosidion Limited (GB) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006059164-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LIMITED (GB) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099176-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PC, GOT2, PDK1 | AADAT 426/4885KYAT1 542/4885KYAT3 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.